The onset of severe acute respiratory syndrome (SARS) in 2002 was attributed to the SARS-CoV-1 coronavirus. Through the application of inventive scientific strategies and stringent research protocols, our organization furnishes a comprehensive solution for the advancement of vaccines and therapeutics targeting SARS-CoV-1.
Overview of SARS-CoV-1
Severe acute respiratory syndrome coronavirus (SARS-CoV-1), a member of the Coronaviridae family, was initially identified in 2002 during an outbreak in Guangdong Province, China. This virus is accountable for the onset of SARS, a condition characterized by severe respiratory distress. Encased in an envelope, SARS-CoV-1 is a positive-sense, single-stranded RNA virus capable of infecting both humans and animals, notably civets and bats. The swift dissemination of SARS-CoV-1 resulted in roughly 8,450 cases and 810 fatalities globally, underscoring its potential to spark significant public health emergencies. Central to its pathogenicity, the spike (S) protein of the virus assumes a pivotal role, facilitating host cell entry through binding to the angiotensin-converting enzyme 2 (ACE2) receptor.
Fig.1 Cell lines that can be used for human coronavirus susceptibility analysis based on cellular receptors. (Aherfi S., et al., 2021)
Vaccine Development for SARS-CoV-1
Inactivated SARS-CoV-1 Vaccines
Examples of inactivated virus vaccines include those developed through formaldehyde therapeutics, UV light, and β-propiolactone. These vaccines were shown to induce virus-neutralizing antibodies in animals, marking a significant step in SARS-CoV-1 vaccine development.
S Protein-based Vaccines
The spike (S) protein of SARS-CoV-1, critical for virus entry into host cells, became a focal point for vaccine development. Vaccines based on the full-length S protein have been shown to induce neutralizing antibodies and protective responses in immunized animals.
Fragment-based Vaccines
Further refinement in vaccine development focused on fragments containing neutralizing epitopes, particularly the receptor-binding domain (RBD) of the S protein. The RBD is responsible for virus binding to the receptor on target cells and contains major neutralizing epitopes.
Therapeutics Development for SARS-CoV-1
The development of antiviral drugs against SARS-CoV-1 focused on both existing medications and the discovery of novel compounds. Key examples include:
- Ribavirin: Originally used for treating hepatitis C, this antiviral drug was tested against SARS-CoV-1 in various in vitro studies, showing variable efficacy.
- Lopinavir/Ritonavir: An HIV protease inhibitor combination, it was repurposed for SARS-CoV-1 and tested in clinical trials, with mixed results.
- Remdesivir: A more recent antiviral, initially developed for Ebola, it was later found to be effective against SARS-CoV-2 and could potentially be repurposed for SARS-CoV-1.
Our Services
Specializing in the development of vaccines and therapeutics targeting SARS-CoV-1, our suite of services is founded on meticulous scientific inquiry and the utilization of state-of-the-art biotechnological methodologies.
- SARS-CoV-1 Infection 129SvEv Mouse Models
- SARS-CoV-1 Infection STAT1-/- Mouse Models
- SARS-CoV-1 Infection hACE2 Transgenic Mouse Models
- SARS-CoV-1 Infection K18-hACE2 Mouse Models
In addition, we also provide the following services:
- Biomarker Identification: Identification of biomarkers that correlate with immune responses and disease outcomes, aiding in the evaluation of vaccine and therapeutic efficacy.
- In Vitro Efficacy Studies: Assessment of vaccine candidates and drug efficacy using cell culture models to determine neutralization capabilities and cellular responses.
If you are interested in our services, please feel free to contact us.
References
- Aherfi, Sarah, et al. "Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV." Future Microbiology 16.17 (2021): 1341-1370.
- Jiang, Shibo, Yuxian He, and Shuwen Liu. "SARS vaccine development." Emerging infectious diseases 11.7 (2005): 1016.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
